Medication info
Candelore 10/8 mg (Rosuvastatin, Candesartan)

Candelore 10/8 mg (Rosuvastatin, Candesartan)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202008719 · Approved 2020.12.11 · Insurance code 657808200

Summary

Main use
Treatment of hypertension and heart failure; improvement of hyperlipidemia; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience of administration.
Child dose
Adolescents and children 18 years of age or younger: Safety and efficacy have not been established. Adolescents and children 18 years of age or younger: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of hyperlipidemia; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients who need to take two drugs, Candesartan Cilexetil and Rosuvastatin, simultaneously. Candesartan Cilexetil is used for the treatment of essential hypertension and for patients with left ventricular dysfunction in heart failure, as an add-on therapy to ACE inhibitors or when tolerability is poor. Rosuvastatin helps control hypercholesterolemia and dyslipidemia in conjunction with diet, and delays the progression of atherosclerosis. Additionally, it reduces the risk of cardiovascular events and is used to decrease the risks of stroke, myocardial infarction, and vascular revascularization in high-risk populations with elevated high-sensitivity C-reactive protein levels. Therefore, this medication is effective for the treatment of patients requiring management of hypertension and cholesterol.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience of administration.

Child dose

Adolescents and children 18 years of age or younger: Safety and efficacy have not been established. Adolescents and children 18 years of age or younger: Safety and efficacy have not been established.

Precautions

This medication can cause severe harm to the fetus if taken during pregnancy, particularly in the second and third trimesters. Therefore, if pregnancy is confirmed, it should be discontinued immediately. Patients who are allergic to any of the components of this medication or have active liver disease should not take it. Pregnant women or nursing mothers, as well as fertile women not using adequate contraception, should not take this medication. Patients with severely impaired liver function and those with muscle disorders should also refrain from taking this medication. Patients with very poor kidney function, those taking certain immunosuppressants, and patients with diabetes or severe renal impairment who are taking certain medications are also contraindicated against this drug. This medication carries a risk of muscle-related side effects, so if symptoms such as myalgia or weakness occur, one should consult a doctor immediately. Elderly patients, those with weak liver function, and those with hyperkalemia should use this medication with caution, and regular blood tests to monitor liver and kidney function and serum potassium levels are important. This medication may interact with other antihypertensives, diuretics, antibiotics, etc., so patients should inform healthcare providers of any other medications they are taking. Side effects such as headaches, dizziness, dyspepsia, and itching may occur during treatment, and if severe skin rash or breathing difficulties occur, the medication should be stopped immediately, and the patient should go to the hospital. This medication may cause dizziness while driving or operating machinery, so caution is advised. Safety and effectiveness in children have not been established, so it is not recommended for them. In case of overdose, symptoms such as hypotension, dizziness, and tachycardia may occur, and immediate treatment at a healthcare facility is required.

Side effects

headache, nasopharyngitis, localized infection, chest discomfort, fatigue, inflammation, systemic pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, positional dizziness, itching, nausea, vascular edema, low back pain, respiratory infection, dizziness, fatigue, peripheral edema, chest pain, bronchitis, cough, sinusitis, nausea, abdominal pain, diarrhea, vomiting, arthralgia, proteinuria, weakness, fever, paresthesia, dyspepsia, gastroenteritis, tachycardia, palpitations, increased creatine kinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, dyspnea, rash, increased sweating, hematuria, leukopenia, neutropenia, agranulocytosis, hyperkalemia, hyponatremia, hypoglycemia, fatigue, hunger, cold sweat, hand tremor, decreased concentration, convulsions, altered consciousness, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, productive cough, exacerbation of hypertension, unstable blood pressure, dizziness, positional vertigo, adrenal insufficiency, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorder, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myopathy, rhabdomyolysis, weakness, headache, dizziness, myalgia, myopathy, rhabdomyolysis, elevated ALT, elevated AST, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular myasthenia, symptomatic hypotension, tachycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture and is best kept at room temperature between 1 to 30 degrees Celsius. Proper storage will ensure the safety and efficacy of the medication.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.